SAN DIEGO, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
In September of 2023, the company released details of its 12-week treatment of severe ulcerative colitis. The results demonstrated that 25.7% of patients who received their treatment showed endoscopic improvement. Following this news, the stock plummeted ...